Managing hypertension in diabetic nephropathy requires a careful, patient-specific approach. In individuals with adequate residual kidney function and appropriate electrolyte levels, a particular class of antihypertensive agent may be added as part of the evidence-based regimen.
Diabetic nephropathy with hypertension in patients who have an eGFR above 30 ml/min/1.73 m² and a serum potassium below 4.8 mmol/L — a profile where the addition of a targeted antihypertensive agent class is supported by evidence.
The protocol involves adding a steroidal mineralocorticoid receptor antagonist (MRA) to address hypertension in the defined patient profile. The complete regimen — including selection, sequencing, and monitoring parameters — is detailed in the full structured protocol.
Full regimen details are available in the protocol below.DOI: 10.1016/j.nefro.2024.11.002
Steroidal mineralocorticoid receptor antagonists (MRA) are probably useful for managing hypertension in patients with eGFR > 30 ml/min/1.73 m2 and serum potassium < 4.8 mmol/L.
View source ↗